[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340102-105":59,"doc-detail-340102-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","correlation-between-plasma-ccfdna-mtdna-changes-ctcs-and-epithelial-mesenchymal-transition-in-breast-cancer-patients-undergoing-nact","Correlation between plasma ccfDNA, mtDNA changes, CTCs, and epithelial-mesenchymal transition in breast cancer patients undergoing NACT","","Breast cancer patients receiving neoadjuvant chemotherapy were evaluated using plasma biomarkers to support treatment selection and response monitoring. The study assessed circulating cell-free DNA (ccfDNA) and mitochondrial DNA (mtDNA) changes as indicators of treatment effectiveness, and compared them with circulating tumor cell (CTC) findings while analyzing associations with epithelial-mesenchymal transition (EMT). Thirty-six patients and 21 healthy controls underwent qPCR-based measurements of specific DNA targets and integrity ratios. After treatment, ccfDNA decreased and mtDNA copy number increased, with integrity patterns unchanged, while marker differences related to disease status.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/correlation-between-plasma-ccfdna-mtdna-changes-ctcs-and-epithelial-mesenchymal-transition-in-breast-cancer-patients-undergoing-nact/340102/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/correlation-between-plasma-ccfdna-mtdna-changes-ctcs-and-epithelial-mesenchymal-transition-in-breast-cancer-patients-undergoing-nact/340102.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main purpose of measuring plasma ccfDNA and mtDNA in this study?","Question",{"text":112,"@type":113},"To evaluate their effectiveness as indicators of treatment response in breast cancer patients undergoing NACT and to explore their potential as monitoring biomarkers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many participants were included, and how were DNA levels measured?",{"text":117,"@type":113},"Thirty-six female breast cancer patients and 21 healthy females were included. qPCR on plasma measured targets including ND1, ND4, ALU115, ALU247, and GAPDH, and DNA integrity was calculated using ALU247/ALU115 and ND4/ND1 ratios.",{"name":119,"@type":110,"acceptedAnswer":120},"What changes were observed after treatment in ccfDNA and mtDNA?",{"text":121,"@type":113},"After treatment, ccfDNA levels significantly decreased and mtDNA copy number significantly increased. There was no significant change in ccfDNA and mtDNA integrity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340102,1790211787,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Turkish Journal of Medical Sciences  \n\n| Volume 54  Number 4 | Article 6 |\n| --- | --- |\n| 2024\u003Cbr>Correlation between plasma ccfDNA, mtDNA changes, CTCs, and epithelial-mesenchymal transition in breast cancer patients undergoing NACT\u003Cbr>BETÜL ÇELİK\u003Cbr>İREM PEKER EYÜBOĞLUSİNAN KOCA MUSTAFA ÜMİT UĞURLU ÖZKAN ALAN\u003Cbr>See next page for additional authors\u003Cbr>Follow this and additional works at: [https://journals.tubitak.gov.tr/medical](https://journals.tubitak.gov.tr/medical) |  |\n\nRecommended Citation  \nÇELİK, BETÜL; PEKER EYÜBOĞLU, İREM; KOCA, SİNAN; UĞURLU, MUSTAFA ÜMİT; ALAN, ÖZKAN; GÜLLÜ AMURAN, GÖKÇE; AKIN TELLİ, TUĞBA; YUMUK, FULDEN; and AKKİPRİK, MUSTAFA (2024) \"Correlation between plasma ccfDNA, mtDNA changes, CTCs, and epithelial-mesenchymal transition in breast cancer patients undergoing NACT,\" Turkish Journal of Medical Sciences: Vol. 54: No. 4, Article 6. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)10.55730/1300-0144.5834  \nAvailable at: [https://journals.tubitak.gov.tr/medical/vol54/iss4/6](https://journals.tubitak.gov.tr/medical/vol54/iss4/6)  \nThis work is licensed under a Creative Commons Attribution 4.0 International License.  \nThis Research Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact [pinar.dundar@tubitak.gov.tr](pinar.dundar@tubitak.gov.tr).  \nCorrelation between plasma ccfDNA, mtDNA changes, CTCs, and epithelial-mesenchymal transition in breast cancer patients undergoing NACT  \nAuthors  \nBETÜL ÇELİK, İREM PEKER EYÜBOĞLU, SİNAN KOCA, MUSTAFA ÜMİT UĞURLU, ÖZKAN ALAN, GÖKÇEGÜLLÜ AMURAN, TUĞBA AKIN TELLİ, FULDEN YUMUK, and MUSTAFA AKKİPRİK  \nThis research article is available in Turkish Journal of Medical Sciences: [https://journals.tubitak.gov.tr/medical/](https://journals.tubitak.gov.tr/medical/)[ ](https://journals.tubitak.gov.tr/medical/)vol54/iss4/6  \n\n| | Turkish Journal of Medical Sciences [http://journals.tubitak.gov.tr/medical/](http://journals.tubitak.gov.tr/medical/) | Turk J Med Sci (2024) 54: 652-665 © TÜBİTAK |\n| --- | --- | --- |\n| | \u003Cbr>Research Article | doi:10.55730/1300-0144.5834 |\n\nCorrelation between plasma ccfDNA, mtDNA changes, CTCs, and epithelialmesenchymal transition in breast cancer patients undergoing NACT  \nBetül ÇELİK1,*􀁋, İrem PEKER EYÜBOĞLU2􀁋, Sinan KOCA3􀁋, M. Ümit UĞURLU4􀁋, Özkan ALAN5􀁋, Gökçe GÜLLÜ AMURAN2􀁋, Tuğba AKIN TELLİ5􀁋, Fulden YUMUK5􀁋, Mustafa AKKİPRİK2􀁋  \n1  \nDepartment of Medical Biology and Genetics, Health Sciences 2  \nDepartment of Medical Biology, School of Medicine,  \nInstitute, Marmara University, İstanbul, Turkiye Marmara University, İstanbul, Turkiye  \n3Department of Medical Oncology, Ümraniye Education Research Hospital, İstanbul, Turkiye 4Department of General Surgery, School of Medicine, Marmara University, İstanbul, Turkiye 5Department of Medical Oncology, School of Medicine, Marmara University, İstanbul, Turkiye  \nReceived: 25.10.2023  Accepted/Published Online: 11.03.2024  Final Version: 23.08.2024  \nBackground/aim: Breast cancer is the most prevalent cancer in women, emphasizing need for noninvasive blood biomarkers to aid in treatment selection. Previous studies have demonstrated elevated levels of plasma circulating cell-free DNA (ccfDNA) in breast cancer patients. Both ccfDNA and mitochondrial DNA (mtDNA) are fragments released into the bloodstream. In this study, we investigated effectiveness of ccfDNA and mtDNA as indicators of treatment response and explored their potential as monitoring biomarkers. Additionally, we compared these markers with circulating tumor cell (CTC) data and assessed their relationship with epithelialmesenchymal transition (EMT) .  \nMaterials and methods: Thirty-six female breast cancer patients and 21 healthy females were included in the study. Quantitative polymerase chain reaction (qPCR) was performed on plasma sa","cbCainN5hwlRQRHx","https://ap.wps.com/l/cbCainN5hwlRQRHx","pdf",1178329,16,"English","# Background/aim\n# Materials and methods\n# Results\n# Conclusion\n# Key words","[{\"question\":\"What was the main purpose of measuring plasma ccfDNA and mtDNA in this study?\",\"answer\":\"To evaluate their effectiveness as indicators of treatment response in breast cancer patients undergoing NACT and to explore their potential as monitoring biomarkers.\"},{\"question\":\"How many participants were included, and how were DNA levels measured?\",\"answer\":\"Thirty-six female breast cancer patients and 21 healthy females were included. qPCR on plasma measured targets including ND1, ND4, ALU115, ALU247, and GAPDH, and DNA integrity was calculated using ALU247/ALU115 and ND4/ND1 ratios.\"},{\"question\":\"What changes were observed after treatment in ccfDNA and mtDNA?\",\"answer\":\"After treatment, ccfDNA levels significantly decreased and mtDNA copy number significantly increased. There was no significant change in ccfDNA and mtDNA integrity.\"}]","Correlation between plasma ccfDNA, mtDNA changes, CTCs, and epithelial-mesenchymal transition in breast cancer patients undergoing NACT | PDF",1790034188,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1ece1938df4f85426221ea86b4cbe27.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad5b93a2a67c42e4a3ee388492b34079.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f95574f187d7db657c9c00f3d405e01b.webp",981,1383,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09eba54f860d6055c52c285efd00234f.webp",980,1382]